EyePoint Pharmaceuticals (EYPT) Announces Proposed Common Share Offering

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by EyePoint. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, EyePoint intends to grant the underwriters a thirty-day option to purchase up to an additional 15 percent of shares of its common stock offered in the public offering.

Cowen and Guggenheim Securities are acting as joint book-running managers for the offering.

EyePoint intends to use the net proceeds from the offering for the advancement of EYP-1901 for wet AMD, for pipeline and commercial programs, and for general corporate purposes.

The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-252170) previously filed with the Securities and Exchange Commission (SEC) on January 15, 2021 and declared effective by the SEC on January 25, 2021.

The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the registration statement.

You May Also Be Interested In

• Atossa Therapeutics closes $4.5 million registered direct offering
• Shake Shack names Christiane Pendarvis to board of directors
• BIG3 Basketball to go public via Graf Global merger at $290 million